PL3071230T3 - Kompozycje do leczenia reumatoidalnego zapalenia stawów oraz sposoby ich stosowania - Google Patents

Kompozycje do leczenia reumatoidalnego zapalenia stawów oraz sposoby ich stosowania

Info

Publication number
PL3071230T3
PL3071230T3 PL14812084T PL14812084T PL3071230T3 PL 3071230 T3 PL3071230 T3 PL 3071230T3 PL 14812084 T PL14812084 T PL 14812084T PL 14812084 T PL14812084 T PL 14812084T PL 3071230 T3 PL3071230 T3 PL 3071230T3
Authority
PL
Poland
Prior art keywords
compositions
treatment
methods
same
rheumatoid arthritis
Prior art date
Application number
PL14812084T
Other languages
English (en)
Polish (pl)
Inventor
Xiaohong Huang
Martine JASSON
Vanessa MARKS
Allen Radin
Chungpeng FAN
Hubert VAN HOOGSTRATEN
Stefano FIORE
Janet VAN ADELSBERG
Mark Genovese
Original Assignee
Sanofi Biotechnology
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology, Regeneron Pharmaceuticals, Inc. filed Critical Sanofi Biotechnology
Publication of PL3071230T3 publication Critical patent/PL3071230T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL14812084T 2013-11-22 2014-11-21 Kompozycje do leczenia reumatoidalnego zapalenia stawów oraz sposoby ich stosowania PL3071230T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361907796P 2013-11-22 2013-11-22
US201462008787P 2014-06-06 2014-06-06
EP14306366 2014-09-05
PCT/US2014/066856 WO2015077582A1 (en) 2013-11-22 2014-11-21 Compositions for the treatment of rheumatoid arthritis and methods of using same
EP14812084.3A EP3071230B1 (en) 2013-11-22 2014-11-21 Compositions for the treatment of rheumatoid arthritis and methods of using same

Publications (1)

Publication Number Publication Date
PL3071230T3 true PL3071230T3 (pl) 2020-09-21

Family

ID=51518724

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14812084T PL3071230T3 (pl) 2013-11-22 2014-11-21 Kompozycje do leczenia reumatoidalnego zapalenia stawów oraz sposoby ich stosowania

Country Status (11)

Country Link
US (1) US20160280782A1 (https=)
EP (2) EP3770173A1 (https=)
JP (4) JP6657089B2 (https=)
KR (3) KR20230155586A (https=)
CN (2) CN120514847A (https=)
AU (3) AU2014352801B2 (https=)
CA (1) CA2930615C (https=)
MX (2) MX377190B (https=)
PL (1) PL3071230T3 (https=)
SG (1) SG10201804000TA (https=)
WO (1) WO2015077582A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
AU2014352801B2 (en) * 2013-11-22 2020-05-28 Regeneron Pharmaceuticals, Inc. Compositions for the treatment of rheumatoid arthritis and methods of using same
IL319993A (en) 2015-11-03 2025-06-01 Sanofi Biotechnology Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same
BR112018067851A2 (pt) * 2016-03-07 2019-02-05 Regeneron Pharma composições e métodos para o tratamento de artrite reumatoide
EP3216461A1 (en) * 2016-03-07 2017-09-13 Sanofi Biotechnology Compositions and methods for treating rheumatoid arthritis
WO2019111938A1 (ja) 2017-12-07 2019-06-13 藤森工業株式会社 ポート付バッグおよびキャップ付バッグ
AU2019329958B2 (en) * 2018-08-29 2025-05-29 Regeneron Pharmaceuticals, Inc. Methods and compositions for treating subjects having rheumatoid arthritis
BR112021014377A2 (pt) 2019-01-31 2021-12-28 Regeneron Pharma Composições e métodos para o tratamento de artrite idiopática juvenil
AU2020261431A1 (en) * 2019-04-24 2021-12-09 Regeneron Pharmaceuticals, Inc. Methods of diagnosis and treatment of rheumatoid arthritis
EP3980459A1 (en) * 2019-06-04 2022-04-13 Sanofi Biotechnology Compositions and methods for treating pain in subj ects with rheumatoid arthritis
JP7373958B2 (ja) 2019-09-27 2023-11-06 株式会社日立製作所 分析システム及び分析方法
KR20210040735A (ko) 2019-10-05 2021-04-14 양수현 천장 수납형 빨래 건조대
US12254347B2 (en) * 2021-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Data pipeline

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US8080248B2 (en) * 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
AU2014352801B2 (en) * 2013-11-22 2020-05-28 Regeneron Pharmaceuticals, Inc. Compositions for the treatment of rheumatoid arthritis and methods of using same
ES2799439T3 (es) * 2013-11-22 2020-12-17 Sanofi Biotechnology Composiciones para el tratamiento de la artritis reumatoide y métodos de uso de las mismas

Also Published As

Publication number Publication date
AU2020223706A1 (en) 2020-09-10
EP3071230B1 (en) 2020-04-08
MX377190B (es) 2025-03-07
JP2016539125A (ja) 2016-12-15
SG10201804000TA (en) 2018-07-30
MX2016006595A (es) 2016-09-06
AU2020223706B2 (en) 2024-04-18
CA2930615A1 (en) 2015-05-28
WO2015077582A1 (en) 2015-05-28
AU2014352801A1 (en) 2016-06-23
CA2930615C (en) 2023-04-04
JP2022033891A (ja) 2022-03-02
AU2014352801B2 (en) 2020-05-28
CN120514847A (zh) 2025-08-22
US20160280782A1 (en) 2016-09-29
CN106413748A (zh) 2017-02-15
MX2020011993A (es) 2021-01-29
JP2026032035A (ja) 2026-02-25
EP3071230A1 (en) 2016-09-28
EP3770173A1 (en) 2021-01-27
AU2024204881A1 (en) 2024-08-15
KR20160079121A (ko) 2016-07-05
KR20220056254A (ko) 2022-05-04
JP2024026223A (ja) 2024-02-28
KR20230155586A (ko) 2023-11-10
JP6657089B2 (ja) 2020-03-04

Similar Documents

Publication Publication Date Title
IL273090B (en) Methods and preparations for the treatment of cancer
PL3071230T3 (pl) Kompozycje do leczenia reumatoidalnego zapalenia stawów oraz sposoby ich stosowania
SG11201601412XA (en) Compositions and methods for the treatment of presbyopia
IL232001A0 (en) Preparations for the treatment of rheumatoid arthritis and methods of using them
ZA201701244B (en) Carrier-antibody compositions and methods of making and using the same
IL265876A (en) Preparations that include 15-ohepa and methods of using them
SG11201509136YA (en) Cenicriviroc compositions and methods of making and using the same
IL244622A0 (en) Preparations for the treatment of hypertension and/or fibrosis
IL244621A0 (en) Preparations for the treatment of hypertension and/or fibrosis
PL2968478T3 (pl) Kompozycje i sposoby do leczenia karboksyhemoglobinemii
PL3113774T3 (pl) Kompozycje grapiprantu i sposoby ich zastosowania
EP3068431A4 (en) Methods and compositions for the treatment of hcmv
PT3071230T (pt) Composições para o tratamento da artrite reumatoide e métodos de utilização das mesmas
IL239812A0 (en) Method and composition for the treatment of arthritis and osteoarthritis
IL286709B1 (en) Preparations for the treatment of rheumatoid arthritis and methods of using them
GB201300628D0 (en) Compositions comprising 15-OHEPA and methods of using the same